This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar. 65(2): 87–108.TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin2015Mar.6528710810.3322/caac.2126225651787Search in Google Scholar
Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. J Natl Cancer Inst. 2005; 97: 188–194.MauriDPavlidisNIoannidisJPANeoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-AnalysisJ Natl Cancer Inst.20059718819410.1093/jnci/dji02115687361Search in Google Scholar
Bartlett JM1, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol. 2011; 29: 1531–1538.BartlettJM1BrookesCLRobsonTvan de VeldeCJBillinghamLJCampbellFMEstrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trialJ Clin Oncol.2011291531153810.1200/JCO.2010.30.3677308297321422407Search in Google Scholar
Zhang N, Moran MS, Huo Q, Haffty BG, Yang Q. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest. 2011; 29: 594–598.ZhangNMoranMSHuoQHafftyBGYangQThe hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysisCancer Invest.20112959459810.3109/07357907.2011.62191322011281Search in Google Scholar
Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005; 92: 147–155.BurcombeRJMakrisARichmanPIDaleyFMNobleSPittamMEvaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancerBr J Cancer.20059214715510.1038/sj.bjc.6602256236175015611798Search in Google Scholar
Shet T, Agrawal A, Chinoy R, Havaldar R, Parmar V, Badwe R. Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy—implications for a pathologist. Breast J. 2007; 13: 457–464.ShetTAgrawalAChinoyRHavaldarRParmarVBadweRChanges in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy—implications for a pathologistBreast J.20071345746410.1111/j.1524-4741.2007.00465.x17760666Search in Google Scholar
Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012; 19: 3002–3011.ChenSChenCMYuKDZhouRJShaoZMPrognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancerAnn Surg Oncol.2012193002301110.1245/s10434-012-2318-222437200Search in Google Scholar
HER-2/neu expression in locally advanced breast carcinomas: pre-and post-neoadjuvant chemotherapy. Quddus RM, Sung JC, Zhang C, Pasqueriello T, Eklund M, Steinhoff MM Breast Cancer. 2005; 12(4): 294–8.HER-2/neu expression in locally advanced breast carcinomas: pre-and post-neoadjuvant chemotherapyQuddusRMSungJCZhangCPasquerielloTEklundMSteinhoffMMBreast Cancer2005124294810.2325/jbcs.12.29416286910Search in Google Scholar
Giuliano AE1, Connolly JL2, Edge SB3, Mittendorf EA4, Rugo HS5, Solin LJ6, et al. (2017) Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67: 290–303.GiulianoAE1ConnollyJL2EdgeSB3MittendorfEA4RugoHS5SolinLJ62017Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manualCA Cancer J Clin6729030310.3322/caac.2139328294295Search in Google Scholar
Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410.ElstonCWEllisIO2002Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-upHistopathology1940341010.1111/j.1365-2559.1991.tb00229.x1757079Search in Google Scholar
van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 2011; 37: 422–430.van de VenSSmitVTDekkerTJNortierJWKroepJRDiscordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancerCancer Treat Rev.20113742243010.1016/j.ctrv.2010.11.00621177040Search in Google Scholar
Zhang N, Moran MS, Huo Q, Haffty BG, Yang Q. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest. 2011; 29: 594–598.ZhangNMoranMSHuoQHafftyBGYangQThe hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysisCancer Invest.20112959459810.3109/07357907.2011.62191322011281Search in Google Scholar
Bertos NR, Park M. Breast cancer - one term, many entities? J Clin Invest. 2011; 121: 3789–3796.BertosNRParkMBreast cancer - one term, many entities?J Clin Invest.20111213789379610.1172/JCI57100319546521965335Search in Google Scholar
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429–4434.DentRTrudeauMPritchardKIHannaWMKahnHKSawkaCATriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res.2007134429443410.1158/1078-0432.CCR-06-304517671126Search in Google Scholar
Hirata T1, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer. 2009; 101: 1529–1536. doi: 10.1038/sj.bjc.6605360.HirataT1ShimizuCYonemoriKHirakawaAKounoTTamuraKChange in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancerBr J Cancer20091011529153610.1038/sj.bjc.6605360277852519809429Open DOISearch in Google Scholar
Xi Jin1, Yi-Zhou Jiang1, Sheng Chen1, Ke-Da Yu1, Zhi-Ming Shao1, Gen-Hong Di. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. Oncotarget, Vol. 6, No. 11, 2015.Jin1XiJiang1Yi-ZhouChen1ShengYu1Ke-DaShao1Zhi-MingDiGen-HongPrognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational studyOncotarget611201510.18632/oncotarget.3292449624225826079Search in Google Scholar
Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012; 19: 3002–3011. doi: 10.1245/s10434-012-2318-2.ChenSChenCMYuKDZhouRJShaoZMPrognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancerAnn Surg Oncol.2012193002301110.1245/s10434-012-2318-222437200Open DOISearch in Google Scholar
Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996; 14: 1718–1729.BinesJOleskeDMCobleighMAOvarian function in premenopausal women treated with adjuvant chemotherapy for breast cancerJ Clin Oncol.1996141718172910.1200/JCO.1996.14.5.17188622093Search in Google Scholar
Rose DP, Davis TE. Effects of Adjuvant Chemohormonal Therapy on the Ovarian and Adrenal Function of Breast Cancer Patients. Cancer Res. 1980; 40: 4037–4047.RoseDPDavisTEEffects of Adjuvant Chemohormonal Therapy on the Ovarian and Adrenal Function of Breast Cancer PatientsCancer Res.19804040374047Search in Google Scholar
Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol. 2016; 27: 480–487. doi: 10.1093/annonc/mdv611.NiikuraNTomotakiAMiyataHIwamotoTKawaiMAnanKChanges in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registryAnn Oncol.20162748048710.1093/annonc/mdv61126704052Open DOISearch in Google Scholar
Matsubara N1, Mukai H, Masumoto M, Sasaki M, Naito Y, Fujii S, Wada N. Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. Breast Cancer Res Treat. 2014; 147: 95–102. doi: 10.1007/s10549-014-3084-6.MatsubaraN1MukaiHMasumotoMSasakiMNaitoYFujiiSWadaNSurvival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCRBreast Cancer Res Treat20141479510210.1007/s10549-014-3084-625106660Open DOISearch in Google Scholar
Matsubara N, Mukai H, Fujii S, Wada N. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res Treat. 2013; 137: 203–212. doi: 10.1007/s10549-012-2344-6.MatsubaraNMukaiHFujiiSWadaNDifferent prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancerBreast Cancer Res Treat201313720321210.1007/s10549-012-2344-623184081Open DOISearch in Google Scholar